The clinical-stage biotech highlighted in today’s article – operating in the hot immuno-oncology sector – has both long-term and short-term bull cases to be made for it, with the author finding the short-term bull thesis – that the stock is currently undervalued following a major partnership deal – to be particularly compelling. Here’s some of what he has to say: “Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a penchant for striking lucrative deals with big pharma, the future looks bright for [this company]”. For more, CLICK HERE.